Literature DB >> 26442513

Artocarpus altilis CG-901 alters critical nodes in the JH1-kinase domain of Janus kinase 2 affecting upstream JAK/STAT3 signaling.

Oyekanmi Nash1,2,3, Olaposi Omotuyi4,5,6, Joonku Lee7, Byoung-Mog Kwon8, Lucy Ogbadu1.   

Abstract

As a key step in achieving low-cost, easily accessible anti-cancer therapy for low- and middle-income countries, we recently established the scientific basis for the folkloric use of Artocarpus altilis for the treatment of cancer by investigating the geranyl dihydrochalcone (CG-901) content and its interference with signal transducer and activator of transcription 3 (STAT3) phosphorylation and blockage of further downstream signaling. In the current study, the CG-901 upstream target was queried by chemical fingerprinting similarity assessment, semi-empirical (PM6ESCF) QMMM and molecular dynamics (MD) simulation. Moderate (∼0.4) to high (∼0.7) Tanimoto scores were found when the CG-901 scaffold was compared to ligands co-crystallized with Janus kinases (JAK) 1-3. High negative energy values were obtained when the CG-901 was treated semi-empirically (PM6ESCF) within the classical field of JAK (1-3). Multiple nanosecond MD simulations showed that CG-901 did not cause any large structural perturbations in the nucleotide-binding, activation and catalytic loops within the kinase (JH1) domain of JAK (1-3); however, it reduced the energy required to attain metastability along the path to energy minima conformation. In comparison to JAK1 and Apo-state JAK2, JAK2-bound CG-901 exhibited a highly re-organized key intra-domain protein network; indicating atomic level interference with inter-residue communication. In conclusion, CG-901 isolated from A. altilis represents a broad-spectrum JAK inhibitor, which may underlie the mechanism of STAT3 phosphorylation blockage. Graphical abstract Upper panel Janus kinase 2 upstream signaling pathway. Lower panel Apo-JAK2 (left) and CG-901-bound JAK2 (right).

Entities:  

Keywords:  Anticancer; Artocarpus altilis; Critical nodes; Geranyl dihydrochalcone; Janus kinase; STAT3

Mesh:

Substances:

Year:  2015        PMID: 26442513     DOI: 10.1007/s00894-015-2821-z

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  43 in total

Review 1.  Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.

Authors:  John J O'Shea; Massimo Gadina; Robert D Schreiber
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

2.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

3.  CHARMM-GUI: a web-based graphical user interface for CHARMM.

Authors:  Sunhwan Jo; Taehoon Kim; Vidyashankara G Iyer; Wonpil Im
Journal:  J Comput Chem       Date:  2008-08       Impact factor: 3.376

4.  Grcarma: A fully automated task-oriented interface for the analysis of molecular dynamics trajectories.

Authors:  Panagiotis I Koukos; Nicholas M Glykos
Journal:  J Comput Chem       Date:  2013-10-05       Impact factor: 3.376

5.  An extensible interface for QM/MM molecular dynamics simulations with AMBER.

Authors:  Andreas W Götz; Matthew A Clark; Ross C Walker
Journal:  J Comput Chem       Date:  2013-10-09       Impact factor: 3.376

6.  Activation of the JAK/STAT pathway in Behcet's disease.

Authors:  A Tulunay; M G Dozmorov; F Ture-Ozdemir; V Yilmaz; E Eksioglu-Demiralp; F Alibaz-Oner; G Ozen; J D Wren; G Saruhan-Direskeneli; A H Sawalha; H Direskeneli
Journal:  Genes Immun       Date:  2015-03       Impact factor: 2.676

7.  Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway.

Authors:  E S Park; H Kim; J M Suh; S J Park; S H You; H K Chung; K W Lee; O Y Kwon; B Y Cho; Y K Kim; H K Ro; J Chung; M Shong
Journal:  Mol Endocrinol       Date:  2000-05

8.  Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.

Authors:  Maria Gabriella Brasca; Paola Gnocchi; Marcella Nesi; Nadia Amboldi; Nilla Avanzi; Jay Bertrand; Simona Bindi; Giulia Canevari; Daniele Casero; Marina Ciomei; Nicoletta Colombo; Sabrina Cribioli; Gabriele Fachin; Eduard R Felder; Arturo Galvani; Antonella Isacchi; Ilaria Motto; Achille Panzeri; Daniele Donati
Journal:  Bioorg Med Chem       Date:  2015-03-28       Impact factor: 3.641

9.  A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.

Authors:  Shashidhar S Jatiani; Stephen C Cosenza; M V Ramana Reddy; Ji Hee Ha; Stacey J Baker; Ajoy K Samanta; Matthew J Olnes; Loretta Pfannes; Elaine M Sloand; Ralph B Arlinghaus; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-04

Review 10.  Mechanisms of drug resistance in cancer chemotherapy.

Authors:  Y A Luqmani
Journal:  Med Princ Pract       Date:  2005       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.